EdU CNS Tumor Therapy That Crosses the Blood-Brain Barrier

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer therapies for central nervous system (CNS) tumors are limited by the blood-brain and blood-spinal cord barriers, which prevent many therapeutic agents from crossing and require direct administration, restricting treatment options.

Innovation Solution

Administration of 5-ethynyl-2'-deoxyuridine (EdU) or nucleic acid molecules comprising EdU to treat, inhibit, or kill CNS tumors, bypassing the BBB and BSCB, and utilizing nucleotide excision repair mechanisms to target cancer cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer therapeutics are used to treat CNS tumors, then treatment effectiveness is improved, but the blood-brain barrier prevents the therapeutics from crossing into the CNS

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidblood-brain barrier obstruction

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical structure of thymidine to create EdU (5-ethynyl-2'-deoxyuridine), changing the physical-chemical parameters of the therapeutic agent to enable it to cross the blood-brain barrier while retaining its cancer-fighting properties. This structural modification allows the drug to penetrate the BBB and reach CNS tumors effectively.

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If direct administration into the brain is performed to bypass the blood-brain barrier, then therapeutic delivery is improved, but treatment complexity and invasiveness increase

Engineering Contradiction:

Improvetherapeutic deliveryVSAvoidadministration complexity

Core Design Contradiction:

Ease of operationVSDevice complexity

Solution Approach 1:

The EdU compound possesses inherent properties that allow it to cross the blood-brain barrier autonomously without requiring direct brain injection or specialized delivery devices. The drug administers itself systemically through standard routes (oral or intravenous), eliminating the need for invasive procedures while maintaining therapeutic effectiveness.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

EdU effectively treats and inhibits CNS tumors by penetrating the blood-brain and blood-spinal cord barriers, providing therapeutic options for CNS cancers that were previously inaccessible.

Implementation Method 1

The present invention overcomes previous shortcomings in the art by providing methods and compositions for treating cancers located within in the central nervous system

Methodology Applied

Scientific EffectPassive diffusion: Diffusion

Implementation Method 2

utilizing nucleotide excision repair mechanisms to target cancer cells

Methodology Applied

Scientific EffectNucleotide excision repair: Enzyme

Data Source

PatentUS20260034158A1Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine

Publication Date: 2026.02.05 THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

AI summary

The present invention relates generally to the fields of cancer cell biology, cancer therapeutics for cancers located within in the central nervous system, thymidine analogs and cellular nucleotide excision repair mechanisms. More specifically, the invention relates to the use of EdU in methods of treating cancers located within in the central nervous system, and methods of inhibiting and/or reducing growth of a cancer or cancer cell.